Rubedo Life Sciences and SVAX have announced a strategic partnership aimed at advancing longevity science and biotechnology innovation, unveiled during the Future Investment Initiative (FII) Week in Riyadh. According to the companies, the collaboration seeks to accelerate the development and commercialization of therapies targeting age-related diseases and to support the growth of Saudi Arabia’s biotechnology ecosystem.
The partnership will focus on leveraging Rubedo’s discovery platform, designed to identify and develop novel therapeutics that target senescent cells associated with aging and chronic disease. SVAX, a biotechnology platform backed by the Saudi sovereign wealth fund, will work alongside Rubedo to establish research and development capabilities in the Kingdom.
The company said that this alliance aligns with Saudi Arabia’s Vision 2030 objectives, which emphasize diversification of the economy through investments in life sciences and advanced health technologies. Rubedo added that the collaboration will also explore opportunities for technology transfer, local manufacturing, and regional clinical studies.
According to the company, the partnership represents an important step toward expanding Rubedo’s global presence and advancing its pipeline of small molecule drugs designed to improve longevity and healthspan. Both parties intend to pursue joint research initiatives that could lead to new therapeutic discoveries for aging-related conditions, contributing to Saudi Arabia’s growing role as a hub for biotechnology innovation.
The post Rubedo Life Sciences and SVAX form partnership at Riyadh investment event appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
